SCHEMBL24433665

SCHEMBL24433665

Cc1ccc(CCN(C)C(=N)N(C)CN)o1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.39
POLB P06746 1/20 0.38
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
CHRM1 P11229 1/20 0.35
CYP2C9 P11712 1/20 0.35
CHRM3 P20309 1/20 0.35
MAPT P10636 4/20 0.34
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
ESR2 Q92731 1/20 0.33
PKM P14618 3/20 0.33
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14868751 0.84 ALOX5 (0.41) ALOX5POLBMEN1KMT2ACHRM2
SCHEMBL14868641 0.77 ALOX5 (0.40) ALOX5POLBMEN1KMT2ACHRM2
SCHEMBL14868640 0.73 ALOX5 (0.38) ALOX5POLBMEN1KMT2ACHRM2
SCHEMBL14868700 0.72 POLB (0.36) ALOX5POLBMEN1KMT2ACHRM2
SCHEMBL1362084 0.68
SCHEMBL1868584 0.68
SCHEMBL14868728 0.68 ALOX5 (0.50) ALOX5POLBMEN1KMT2ACHRM2
SCHEMBL6475097 0.68 CHRM2 (0.58) ALOX5POLBMEN1KMT2ACHRM2
SCHEMBL9832426 0.67 ALOX5 (0.71) ALOX5POLBMEN1KMT2AMAPT
SCHEMBL3192132 0.67 MCHR1 (0.52) ALOX5MAPTALDH1A1PKMHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220151957-A1 BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS ANJI PHARMACEUTICALS INC. 2022-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220151957-A1 BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS SLC5A2, SLC5A1, GPR119 ALOX5 2462/4885POLB 3200/4885MEN1 679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.